Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination With Panitumumab Versus Panitumumab Alone in Subject With Wild-Type KRAS Metastatic Colorectal Cancer

NCT00788957 is registered in ClinicalTrials.gov with NantBioScience, Inc. as lead sponsor.

NCT NCT00788957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00788957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination With Panitumumab Versus Panitumumab Alone in Subject With Wild-Type KRAS Metastatic Colorectal Cancer
Lead sponsor
NantBioScience, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 27, 2008
Completion date
July 23, 2010
Enrollment
177 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, colorectal cancer, gastrointestinal cancer, metastatic colorectal cancer, rectal cancer